Useful Links

Useful Links

BUY NOW

  

|

BUY NOW

Proven results in Type 2 diabetes - Now you know

Proven results in Type 2 diabetes - Now you know

FreeStyle Libre is clinically proven to reduce HbA1c in people living with type 2 diabetes (T2D)18,21,27,28

Non-insulin therapy

A1c inside a circle next to a wide blue downwards arrow showing a decrease of 1.6 percent.

After 22 weeks

In people with T2D who were using non-insulin therapy and FreeStyle Libre (p<0.001 vs. baseline A1c)27

Basal insulin users

A1c inside a circle next to a wide blue downwards arrow showing a decrease of 1.1 percent.

After 22 weeks

In people with T2D who were using basal insulin and FreeStyle Libre (p<0.001 vs. baseline A1c)27

A downward pointing yellow arrow.

Baseline A1c:

10.1%

Follow-up A1c:

8.5%

Lowering HbA1c reduces your risk of diabetes related complications

 

Non-insulin therapy

A1c inside a circle next to a wide blue downwards arrow showing a decrease of 0.9 percent.

At 24 weeks

In people with T2D who were using non-insulin therapy and FreeStyle Libre system (p<0.0001)21

Patients with T2D on MDI

A1c inside a circle next to a wide blue downwards arrow showing a decrease of 0.82 percent.

In 10 weeks

In people with T2D on MDI using the FreeStyle Libre system saw a significant A1c reduction compared to SMBG (0.82% vs 0.33%, respectively, p=0.005)28

 

In patients with T2D, oral medications have shown to reduce A1c by 0.60% to 1.12%18

Abbreviations: A1: glycated haemoglobin; MDI: multiple daily injections; SMBG: self-monitoring of blood glucose; T2D: type 2 diabetes.

References: 18. Hirst JA, et al. Diabetes Care. 2012;35(2):446–454. 21. Miller E, Brandner L, Wright E. HbA1c reduction after initiation of the FreeStyle Libre system in type 2 diabetes patients on long-acting insulin or non-insulin therapy [84-LB]. Poster presented at: 80th Scientific Sessions of the American Diabetes Association; June 12-16, 2020;Virtual. 27. Wright E, et al. Diabetes Spectrum. 2021;34(2):184–189. 28. Yaron, M. Diabetes Care 2019;42(7):1178–1184.

Cookie Policy and Disclaimer

FreeStyle Libre uses cookies to give you the best website experience. By using our website, you consent to the use of cookies per our privacy policy. FreeStyle.abbott/my-en is a product specific website only intended for residents of the Malaysia.

Change country
Malaysia (en-MY)

The FreeStyle Libre flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus. The indication for children (age 4 – 17) is limited to those who are supervised by a caregiver at least 18 years old who is responsible for supervising, managing, and assisting the child in using the FreeStyle Libre system and interpreting its readings.

Health care professionals and consumers should be aware about the limitations of available scientific evidence for use of this device in any other groups of patients who require diabetes management. Always read the label and use as directed.

Please consult your healthcare professional for the interpretation of result and diagnosis. Registered under ACT 737 – Reg. No: GC47794107716. MDAMD 0407/2022.

Abbott Logo

© 2022 Abbott. FreeStyle, Libre, and related brand marks are marks of Abbott. ADC-64229 v1.0

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?